drugset / Trial / NCT03707717
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
Timeline
- Start
- 2018-10-15
- Primary completion
- 2019-06-05
- Completion
- 2019-06-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bimekizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.